BTC Health (ASX:BTC) Expands Distribution Partnership with Arna Pharma
BTC Health (ASX:BTC) extends partnership with Arna Pharma, securing indefinite license and royalty agreements in key markets.
Category: Healthcare
Micro-X Ltd (ASX:MX1) Raises $3.3M in Capital Placement
Micro-X Ltd (ASX:MX1) successfully raises $3.3M through capital placement, focusing on medical imaging and strategic partnerships.
CLINUVEL Pharmaceuticals Limited (ASX:CUV) Reports Preliminary CUV052 Study Results
CLINUVEL (ASX:CUV) releases preliminary results from the CUV052 study, supporting SCENESSE®’s safety in adolescent EPP patients.
Smartgroup Corporation Ltd (ASX:SIQ) Secures Monash Health Contract for Salary Packaging
Smartgroup Corporation Ltd (ASX:SIQ) secures a contract with Monash Health to provide salary packaging and novated leasing services for 25,000 employees.
PYC Therapeutics (ASX:PYC) Receives Approval to Begin Human Trials for PKD Treatment
PYC Therapeutics (ASX:PYC) receives regulatory approval to commence human trials for its PKD drug candidate, PYC-003.
Radiopharm Theranostics (ASX:RAD) Reports Successful Detection of Brain Metastases with RAD 101
Radiopharm Theranostics (ASX:RAD) announces successful clinical trial results for RAD 101 in detecting brain metastases, advancing their oncology portfolio.
Mayne Pharma Group Limited (ASX:MYX) Announces 1H FY25 Market Update
Mayne Pharma (ASX:MYX) expects 12-14% revenue growth and a 275-300% EBITDA increase for 1H FY25, driven by key sectors.
Ansell Limited (ASX:ANN) Announces Half Year Results and Interim Dividend
Ansell Limited (ASX:ANN) reports a 29.9% revenue increase for H1 and announces an interim dividend of 22.20 US cents per share.
Neuren Pharmaceuticals (ASX:NEU) Receives Priority Review Voucher Sale Proceeds
Neuren Pharmaceuticals (ASX:NEU) receives one-third of proceeds from Priority Review Voucher sale, boosting its financial position.
Nyrada Inc (ASX:NYR) Initiates Phase Ia Clinical Trial
Nyrada Inc (ASX:NYR) has commenced its Phase Ia clinical trial for NYR-BI03, following HREC approval.